RE:RE:RE:New job posting So every cancer drug that makes it to clinic by definition passes preclinical and only 6% make it to approval so THTX are in the majority. Even passing Ph1 is only 60:40 odds I think. I'm pretty sure many of those fails thought they had som3thing special. Unfortunately I don't think this is completely unsurprising.
SPCEO1 wrote: That reads to me like an indictment of Christian. Perhaps on further review, the great preclinical work may have had some flaws? Or, it could be they found protocols were not being followed in the phase 1a and 1b leading to the pause due to weird results. There clearly is a big gap between the preclinical results and the still unknown phase 1a and 1b results, so I am sure they are trying to figure that out.
scarlet1967 wrote: "Audit activities to ensure that Theratechnologies pre-clinical and clinical studies are conducted according to protocols and that any deviation is documented and assessed"
THTX isn't involved with any preclinical studies but Sort1!!